Flamel Technologies SA (NASDAQ:FLML)’s share price was down 3.7% on Monday . The company traded as low as $13.93 and last traded at $13.93, with a volume of 222,423 shares traded. The stock had previously closed at $14.47.

A number of equities analysts have recently weighed in on FLML shares. Zacks Investment Research lowered Flamel Technologies SA from a “hold” rating to a “sell” rating in a research report on Tuesday, May 10th. Leerink Swann reaffirmed a “buy” rating and set a $16.00 target price on shares of Flamel Technologies SA in a research report on Tuesday, May 10th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Flamel Technologies SA presently has a consensus rating of “Buy” and a consensus target price of $18.63.

The company has a market capitalization of $597.17 million and a price-to-earnings ratio of 35.06. The company’s 50 day moving average price is $12.55 and its 200-day moving average price is $10.83.

Flamel Technologies SA (NASDAQ:FLML) last posted its quarterly earnings results on Monday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by $0.08. The company earned $38.90 million during the quarter, compared to analyst estimates of $32.80 million. During the same quarter last year, the firm posted $0.34 EPS. Flamel Technologies SA’s revenue was down 20.0% compared to the same quarter last year. On average, equities research analysts anticipate that Flamel Technologies SA will post ($1.11) earnings per share for the current fiscal year.

Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.